香港济民药业M 中级粉丝 2 注意,他芬喹(tafenoquine)禁用于:葡萄糖-6-磷酸脱氢酶(“G6PD”)缺乏或未知的G6PD状态;当婴儿被发现患有 G6PD 缺乏症时,由哺乳期妇女进行母乳喂养;或者G6PD状态未知;有精神病病史或当前有精神病症状的患者;或已知对他芬喹、其他8-氨基喹啉或ARAKODA的任何成分有过敏反应。登录...
哺乳期妇女哺乳G6PD缺乏症婴儿。 有精神病史或当前有精神病症状的患者。 已知对他非诺喹、其他8-氨基喹啉类药物或ARAKODA成分有过敏反应的患者。 安全性和有效性的持续监测 在临床使用过程中,患者需定期进行检查,以确保药物的安全性和有效性。医务人员应特别关注患者的病史和现有症状,以判断他非诺喹是否适合其使用...
对于G6PD水平正常的易感人群,他非诺喹可以高效安全地预防红内期疟疾。我们以后去疟疾肆虐地旅游或工作时,记得服用他非诺喹预防感染,但之前记得要测定自己的G6PD水平是否正常。 论文来源 1. McCarthy JS, Smith B, Reid M, Berman J, Marquart L, Dobbin C, West L, Read LT, Dow G. Blood schizonticidal...
【Krintafel(tafenoquine,他非诺喹)注意事项】 •溶血性贫血:由于溶血性贫血的风险,必须在开具KRINTAFEL之前进行G6PD测试。监视患者的临床症状或溶血症状。 •妊娠或哺乳期G6PD缺乏症:向患有G6PD缺乏症的胎儿的孕妇服用时,KRINTAFEL可能引起溶血性贫血。不建议在怀孕期间使用KRINTAFEL。缺乏G6PD的婴儿可能通过母乳接...
Letter to the Editor: G6PD Deficiency in the Tafenoquine EraDavid R. SayersBryant J. WebberMedical Surveillance Monthly Report
Hemolytic Anemia: G6PD testing must be performed before prescribing ARAKODA®due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis. G6PD Deficiency in Pregnancy or Lactation: ARAKODA®may ...
Subjects were not enrolled in the study if they had a QT interval corrected for heart rate according to Fridericia’s formula (QTcF) > 450 msec, or if they had any documented phenotypic glucose-6-phosphate dehydrogenase (G6PD) deficiency, with < 70% of local median G6PD activity level ...
他非诺喹跟伯氨喹存在类似的不良反应,最重要的就是G6PD酶缺乏导致的溶血性贫血。由于女性患者中可能存在基因杂合子,G6PD酶活性定性检测可能漏诊这些患者,需要进行定量检测。他非诺喹其他的不良反应包括胃肠道不适(如腹泻、恶心、呕吐),中枢系统反应(头痛、头晕),精神症状(最常见的是嗜睡、多梦和焦虑,亦有发现出现...
deficient or the G6PD status of the infant is unknown [seeCONTRAINDICATIONS]. Advise the woman with a G6PD-deficient infant or if the G6PD status of the infant is unknown not to breastfeed during treatment with ARAKODA and for 3 months after the final dose [seeUse In Specific Populations]....
During monotherapy treatment, the compound exhibits slow parasite and fever clearance times, and toxicity in glucose-6-phosphate dehydrogenase ( G6PD ) deficiency is a concern. Combination with other antimalarials may mitigate these concerns. Methods In 2005, the radical curative efficacy of tafenoquine...